1448960-22-2Relevant academic research and scientific papers
THIAZOLIDINEDIONE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN CANCER TREATMENT
-
, (2015/01/06)
The present invention relates to thiazolidinedione derivatives, to the processes for preparing same and to the therapeutic use thereof for preventing or treating cancer, and more specifically breast cancer. These compounds are of formula (I) and exhibit, at a concentration of 100 μM, a hepatocyte viability preferably greater than 60%, preferably greater than 80% and more preferentially greater than 85%.
Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds
Bordessa, Andrea,Colin-Cassin, Christelle,Grillier-Vuissoz, Isabelle,Kuntz, Sandra,Mazerbourg, Sabine,Husson, Gauthier,Vo, Myriam,Flament, Stéphane,Martin, Hélène,Chapleur, Yves,Boisbrun, Michel
, p. 129 - 140 (2014/07/08)
Δ2-Troglitazone derivatives were shown to exhibit anti-proliferative activity in a PPARγ-independent manner. We prepared various compounds in order to increase their potency and decrease their toxicity towards non-malignant primary cultured hepatocytes. Many compounds induced viabilities less than 20% at 10 μM on various cancer cell lines. Furthermore, five of them showed hepatocyte viability of 80% or more at 200 μM. In addition, compounds 17 and 18 exhibited promising maximum tolerated doses on a murine model, enabling future investigations.
